Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Phase 2/3 Multi-Center Study of SM-88 in Subjects With Pancreatic Cancer Whose Disease Has Progressed or Recurred

Next Previous
Trial Profile

A Randomized Phase 2/3 Multi-Center Study of SM-88 in Subjects With Pancreatic Cancer Whose Disease Has Progressed or Recurred

Status: Discontinued
Phase of Trial: Phase II/III

Latest Information Update: 04 Jul 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Racemetyrosine (Primary) ; Capecitabine; Fluorouracil; Gemcitabine; Methoxsalen; Phenytoin; Sirolimus
  • Indications Adenocarcinoma; Pancreatic cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms TYME-88-PANC
  • Sponsors Tyme Technologies

    • Most Recent Events

    • 26 Jan 2022 According to a Tyme Technologies media release, TYME announced the discontinuation of this trial upon learning that trial sponsor terminated the study arm due to futility. Notwithstanding the discontinuation of this clinical trial, the Company believes there are additional opportunities that could enhance value for TYME stockholders. it believe that being well-capitalized affords it the ability to consider a wide range of strategic options and therefore has commenced a formal process with Moeli
    • 22 Jan 2022 Results presented at the 2022 Gastrointestinal Cancers Symposium
    • 09 Dec 2021 According to a Tyme Technologies media release, final results from the study have been accepted for poster presentation at the 2022 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancer Symposium.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top